{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:34:19Z","timestamp":1791120859183,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,23]],"date-time":"2014-01-23T00:00:00Z","timestamp":1390435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.jhep.2014.01.003","type":"journal-article","created":{"date-parts":[[2014,1,14]],"date-time":"2014-01-14T03:45:51Z","timestamp":1389671151000},"page":"920-927","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4"],"prefix":"10.1016","volume":"60","author":[{"given":"Bradley","family":"Vince","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Lawitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"O\u2019Riordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn R.","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Gruener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricky S.","family":"Mofsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abel","family":"Murillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Donovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"McCarville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Z.","family":"Sullivan-B\u00f3lyai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Mayers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2014.01.003_b0005","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1517\/13543784.2013.806482","article-title":"Review of direct-acting antiviral agents for the treatment of chronic hepatitis C","volume":"22","author":"Shah","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jhep.2014.01.003_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virusres.2012.09.007","article-title":"Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein","volume":"170","author":"Belda","year":"2012","journal-title":"Virus Res"},{"key":"10.1016\/j.jhep.2014.01.003_b0015","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jhep.2013.03.030","article-title":"NS5A inhibitors in the treatment of hepatitis B","volume":"59","author":"Pawlotsky","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.01.003_b0020","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2014.01.003_b0025","unstructured":"Zhou XJ, Vince B, Dubuc-Patrick G, Chen J, Pietropaolo P, Sullivan-Bolyai J, et al. Safety, pharmacokinetic and antiviral activity results from a first-in-human study of IDX719, a pan-genotypic HCV NS5A inhibitor. In: 7th international workshop on clinical pharmacology of hepatitis therapy. Cambridge, MA, USA, June 27; 2012."},{"key":"10.1016\/j.jhep.2014.01.003_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/135965350501000118","article-title":"Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes","volume":"10","author":"Hnatyszyn","year":"2005","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2014.01.003_b0035","unstructured":"Bilello JP, Dousson CB, La Colla M, Chapron C, Bhadresa S, Camire M, et al. Antiviral and preclinical profiles of HCV NS5A inhibitors IDX380 and IDX719. In: 18th international symposium on hepatitis C virus and related viruses. Seattle, WA, USA, September 8\u201312; 2011."},{"key":"10.1016\/j.jhep.2014.01.003_b0040","unstructured":"Bilello JP, La Colla M, Chapron C, Lallos LB, Serra I, Gillum JM, et al. The preclinical profile of the pan-genotypic HCV NS5A inhibitor IDX719 demonstrates its potential for combination therapy. In: 7th international workshop on hepatitis C-resistance and new compounds 2012. Cambridge, MA, USA, June 28; 2012."},{"key":"10.1016\/j.jhep.2014.01.003_b0045","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/hep.24609","article-title":"Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1","volume":"54","author":"Nettles","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.01.003_b0050","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jhep.2011.12.029","article-title":"A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C","volume":"57","author":"Lawitz","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.01.003_b0055","first-page":"400A","article-title":"Dose-ranging study of trial of PPI-461, a potent new pan-genotypic HCV NS5A inhibitor, in patients with HCV genotype-1 infection","volume":"54","author":"Lalezari","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.01.003_b0060","first-page":"1203A","article-title":"BMS-824393 is a potent hepatitis C virus NS5A inhibitor with substantial antiviral activity when given as monotherapy in subjects with chronic G1 HCV infection","volume":"52","author":"Nettles","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.01.003_b0065","first-page":"400A","article-title":"GSK2336805 HCV NS5A inhibitor demonstrates potent antiviral activity in chronic hepatitis C (CHC) genotype 1 infection: results from a first time in human (FITH) single and repeat dose study","volume":"54","author":"Spreen","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.01.003_b0070","doi-asserted-by":"crossref","first-page":"S469","DOI":"10.1016\/S0168-8278(12)61198-2","article-title":"Safety and antiviral activity of ABT-267, a novel NS5A inhibitor, during 3-day monotherapy: first study in HCV genotype-1 (GT1)-infected treatment-naive subjects","volume":"56","author":"Lawitz","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.01.003_b0075","doi-asserted-by":"crossref","first-page":"S480","DOI":"10.1016\/S0168-8278(12)61223-9","article-title":"Novel NS5A inhibitor ACH-2928 phase 1 results in healthy volunteers and HCV GT-1 patients","volume":"56","author":"Vince","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.01.003_b0080","first-page":"1065A","article-title":"PPI-668, a potent new pan-genotypic HCV NS5A inhibitor: phase 1 efficacy and safety","volume":"56","author":"Lalezari","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.01.003_b0085","doi-asserted-by":"crossref","first-page":"S360","DOI":"10.1016\/S0168-8278(13)60878-8","article-title":"ACH-3102, a second generation NS5A inhibitor, demonstrates potent antiviral activity in patients with genotype 1a HCV infection despite the presence of baseline NS5A-resistant variants","volume":"58","author":"Muir","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.01.003_b0090","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0168-8278(13)60005-7","article-title":"Safety and efficacy of interferon-free regimens of ABT-450\/r, ABT-267, ABT-333 \u00b1 ribavirin in patients with chronic HCV GT1 infection: results from the AVIATOR study","volume":"58","author":"Kowdley","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.01.003_b0095","doi-asserted-by":"crossref","first-page":"S573","DOI":"10.1016\/S0168-8278(13)61422-1","article-title":"Interim analysis of an interferon (IFN) \u2013 and ribavirin (RBV) \u2013 free regimen of daclatasvir (DCV), asunaprevir (ASV), and BMS-791325 in treatment-na\u00efve, hepatitis C virus genotype 1-infected patients","volume":"58","author":"Everson","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.01.003_b0100","first-page":"S560","article-title":"Potent viral suppression with all-oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (NS5B inhibitor), \u00b1 ribavirin, intreatment-na\u00efve patients with chronic hepatitis C GT 1, 2, or 3","volume":"56","author":"Sulkowski","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.01.003_b0105","first-page":"243A","article-title":"Once daily sofosbuvir\/ledipasvir fixed dose combination with or without Ribavirin: the ELECTRON trial","volume":"58","author":"Gane","year":"2013","journal-title":"Hepatology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827814000142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827814000142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T19:51:48Z","timestamp":1688932308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827814000142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0168827814000142"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2014.01.003","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2014.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2014 European Association for the Study of the Liver. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}